Search

Search Results

• Phase 3 Clinical Trial of 300 mg Vamotinib Directly Compared with High-Dose Imatinib in Chronic Myeloid Leukemia Patients in Chronic Phase with Failure of Standard-Dose Imatinib: Interim Analysis

  A.G. Turkina, O. Yu. Vinogradova, Е.G. Lomaia, B.A. Bakirov, N.M. Kalimulina, T.V. Shelekhova, I.L. Davydkin, T.I. Pospelova, O.A. Shukhov, E.Yu. Chelysheva, V.A. Shuvaev, S. Lavana, V. Khushoo, S. Apte, T.K. Dolai, R.K. Sahoo, Germes Grigorevich Chilov

  1-13

  01.01.2026

• The Role of Somatic Mutations in Various Genes and the Issue of Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: A Literature Review

  Elena Andreevna Kuzmina, E.Yu. Chelysheva, B.V. Biderman, A.G. Turkina

  10-20

  01.01.2025

• Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)

  Margarita Anatolevna Gurianova, V.I. Kazey, O.A. Shukhov, E.Yu. Chelysheva, A.G. Nikiforova, P.D. Sobolev, M.S. Dolov, D.Yu. Grebenkin, A.N. Petrova, A.V. Bykova, I.S. Nemchenko, E.A. Kuzmina, L.V. Gavrilova, A.V. Kokhno, A.G. Turkina

  347-359

  01.10.2024

• Treatment Outcomes with Asciminib, the First Allosteric BCR::ABL1 Tyrosine Kinase Inhibitor, in Chronic Myeloid Leukemia Patients with Multiple Resistance to Prior Therapy

  A.G. Turkina, Elena Andreevna Kuzmina

  311-320

  09.06.2023

• KIR-Genetic Factors and Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

  Elena Vital’evna Kuzmich, I.E. Pavlova, L.N. Bubnova, S.S. Bessmeltsev

  119-127

  03.03.2023

• Asciminib in Chronic Myeloid Leukemia Patients Without Therapeutic Alternatives: Results of the MAP (Managed Access Program, NCT04360005) Trial in Russia

  A.G. Turkina, Elena Andreevna Kuzmina, E.G. Lomaia, E.V. Morozova, E.Yu. Chelysheva, O.A. Shukhov, A.N. Petrova, T.V. Chitanava, Yu.Yu. Vlasova, I.S. Nemchenko, A.V. Bykova, E.I. Sbityakova, M.A. Gurianova, N.N. Tsyba, A.V. Kokhno, E.N. Parovichnikova

  54-68

  01.01.2023

• Efficacy Predictors of the Third-Line Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase of Chronic Myeloid Leukemia: Results of a Multi-Center Study

  E.G. Lomaia, V.A. Shuvaev, Tamara Vangelevna Chitanava, Yu.D. Matvienko, I.S. Martynkevich, S.V. Voloshin, E.V. Efremova, E.S. Mileeva, M.S. Fominykh, A.E. Kersilova, E.V. Karyagina, N.V. Il’ina, N.V. Dorofeeva, N.V. Medvedeva, A.V. Klimovich, T.V. Shneider, S.A. Stepanova, N.F. Polezhaikovskaya, N.T. Siordiya, E.I. Sbityakova, N.S. Lazorko, E.N. Tochenaya, D.V. Motorin, N.A. Shnalieva, Yu.A. Alekseeva, D.B. Zammoeva, A.Yu. Zaritskey

  271-281

  01.07.2022

• Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Mai

  A.G. Turkina, Margarita Anatolevna Gurianova, E.Yu. Chelysheva, O.A. Shukhov

  54-61

  01.01.2022

• Biological Mechanisms of Sustaining Deep Molecular Response in Chronic Myeloid Leukemia Upon Withdrawal of Tyrosine Kinase Inhibitors

  Ekaterina Yurevna Chelysheva, M.A. Guryanova, A.G. Turkina

  427-435

  01.10.2021

• Factors for Sustaining Molecular Remission after Discontinuation of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia: Results of Non-Randomized Prospective Clinical Trial

  Oleg Aleksandrovich Shukhov, A.N. Petrova, E.Yu. Chelysheva, A.V. Bykova, I.S. Nemchenko, A.G. Turkina

  1-12

  01.01.2021

• Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors

  Margarita Anatolevna Guryanova, E.Yu. Chelysheva, A.G. Turkina

  118-128

  01.01.2021

• EVI1-Positive Leukemias and Myelodysplastic Syndromes: Theoretical and Clinical Aspects (Literature Review)

  Nikolai Nikolaevich Mamaev, A.I. Shakirova, E.V. Morozova, T.L. Gindina

  103-117

  01.01.2021

• New Technology Capabilities of Direct Antiglobulin Test

  Elena Aleksandrovna Poponina, E.V. Butina, A.V. Iovdii, O.D. Maksimov, G.A. Zaitseva, I.V. Paramonov

  426-429

  01.10.2020

• Chronic Myeloid Leukemia: Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors

  Elena Vladislavovna Morozova, Yu.Yu. Vlasova, M.V. Barabanshchikova, N.N. Mamaev, I.M. Barkhatov, A.L. Alyanskii, E.I. Darskaya, M.V. Vladovskaya, S.N. Bondarenko, I.S. Moiseev, B.V. Afanasyev

  193-198

  01.04.2020

• Materials of the II Conference “Current Issues of Diagnosis and Treatment of Ph-Negative and Ph-Positive Myeloproliferative Neoplasms” (March 15–16, 2019; National Research Center for Hematology, Moscow)

  A.L. Melikyan, A.G. Turkina, Irina Nikolaevna Subortseva, E.Yu. Chelysheva, A.M. Kovrigina, V.A. Shuvaev, V.V. Baikov, O.Yu. Vinogradova, S.M. Kulikov, A.N. Petrova, A.V. Bykova, A.-P.A. Poshivai, Yu.Yu. Vlasova, M.M. Chukavina, O.D. Serdyuk, K.V. Naumova, N.T. Siordiya, N.S. Lazorko, R.V. Grozov, E.I. Mullo, A.S. Maksimova, O.M. Senderova, O.V. Kanya, M.S. Fominykh, D.I. Shikhbabaeva, E.A. Belyakova, I.S. Martynkevich, L.B. Polushkina, M.N. Zenina, E.V. Efremova, V.I. Rugal, L.P. Papayan, N.E. Korsakova, O.Yu. Matvienko, E.B. Syrtseva, S.V. Gappoev, M.V. Barabanshchikova, M.O. Ivanova, K.D. Kaplanov, E.S. Rogova, K.B. Trizna, A.S. Zhevnyak, O.E. Ochirova, A.A. Shakhaeva, A.S. Lyamkina, I.P. Mikhno, Yu.B. Chernykh, T.V. Chudanova, I.N. Kontievskii, N.N. Glonina, M.V. Burundukova

  199-230

  01.04.2020

• Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy

  L.M. Makeeva, E.I. Emelina, A.V. Bykova, Gennadii Efimovich Gendlin, G.A. Gusarova, I.G. Nikitin, E.Yu. Chelysheva, O.Yu. Vinogradova, I.E. Lazarev, E.G. Arshanskaya, A.G. Turkina

  104-111

  01.01.2020

• Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)

  Ekaterina Yur’evna Chelysheva, A.G. Turkina, E.S. Polushkina, M.A. Vinogradova, R.G. Shmakov

  202-210

  01.04.2019

• Treatment of Chronic Myeloid Leukemia According to Current Guidelines: The Results of the Pilot Prospective Study “Early Induction Therapy and Monitoring” (РИТМ)

  Oleg Aleksandrovich Shukhov, A.G. Turkina, E.Yu. Chelysheva, A.V. Bykova, A.N. Petrova, G.A. Gusarova, I.S. Nemchenko, A.O. Abdullaev, T.N. Obukhova, A.B. Sudarikov

  194-201

  01.04.2019

• Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia

  V.A. Shuvaev, Ol’ga Yur’evna Vinogradova, I.S. Martynkevich, N.V. Novitskaya, M.S. Fominykh, S.N. Tsareva, D.I. Shikhbabaeva, M.M. Pankrashkina, M.V. Chernikov, N.N. Sharkunov, I.I. Zotova, V.Yu. Udal’eva, E.V. Motyko, S.V. Voloshin

  288-294

  01.10.2018

• Epidemiology of Chronic Myeloid Leukemia in the Republic of Bashkortostan

  N.R. Ryabchikova, Guzyal’ Shagbanovna Safuanova, V.I. Nikulicheva

  349-353

  01.10.2018

• Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

  I.L. Davydkin, Kseniya Viktorovna Naumova, A.M. Osadchuk, I.A. Zolotovskaya, O.E. Danilova, T.Yu. Stepanova, O.V. Tereshina, L.V. Limareva, A.S. Shpigel’, T.P. Kuz’mina

  378-387

  01.10.2018

• Expression of the BCR-ABL1 Gene in Patients with Chronic Myeloproliferative Diseases with Signs of Progression

  L.A. Kesaeva, E.N. Misyurina, D.S. Mar’in, E.I. Zhelnova, A.Yu. Bulanov, A.E. Misyurina, A.A. Krutov, I.N. Soldatova, S.S. Zborovskii, V.A. Misyurin, V.V. Tikhonova, Yu.P. Finashutina, O.N. Solopova, N.A. Lyzhko, A.E. Bespalova, N.N. Kasatkina, A.V. Ponomarev, M.A. Lysenko, Andrei Vital’evich Misyurin

  354-359

  01.10.2018

• Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)

  Vera Vyacheslavovna Tikhonova, M.A. Isakov, V.A. Misyurin, Yu.P. Finashutina, L.A. Kesaeva, N.A. Lyzhko, I.N. Soldatova, N.N. Kasatkina, E.N. Misyurina, A.V. Misyurin

  227-233

  01.07.2018

• Results of Molecular Monitoring in Posttransplant Period by Means of Series Investigation of WT1 Gene Expression in Patients with Acute Myeloid Leukemia

  Ya.V. Gudozhnikova, Nikolai Nikolaevich Mamaev, I.M. Barkhatov, V.A. Katerina, T.L. Gindina, A.I. Shakirova, S.N. Bondarenko, O.A. Slesarchuk, E.I. Darskaya, O.V. Paina, L.S. Zubarovskaya, B.V. Afanas’ev

  241-251

  01.07.2018

• Clinical Significance of the PRAME Gene Expression in Oncohematological Diseases

  Vsevolod Andreevich Misyurin

  26-33

  01.01.2018

• Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice

  Anna Grigor’evna Turkina, N.V. Novitskaya, A.K. Golenkov, V.A. Shuvaev, L.I. Napso, I.V. Krylova, A.M. Savrilova, G.Sh. Safuanova, A.V. Korobkin, T.Yu. Klitochenko, E.V. Burnasheva, E.V. Vasil’ev, O.M. Senderova, E.Yu. Fedorova, L.M. Yalunina, E.K. Nekhai, G.B. Kuchma, A.S. Lyamkina, N.G. Shchedrova

  390-401

  01.07.2017

• The Role of Hypomethylating Agents Prior to Allogeneic Hematopoietic Stem Cells Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

  Varvara Nikolaevna Ovechkina, S.N. Bondarenko, E.V. Morozova, I.S. Moiseev, A.A. Osipova, T.L. Gindina, A.I. Shakirova, T.A. Bykova, A.D. Kulagin, I.A. Samorodova, E.V. Karyakina, E.A. Ukrainchenko, L.S. Zubarovskaya, B.V. Afanas’ev

  351-357

  01.07.2017

• Clinical Recommendations for the Diagnosis and Treatment of Chronic Myeloid Leukemia

  Anna Grigor’evna Turkina, A.Yu. Zaritskii, V.A. Shuvaev, E.Yu. Chelysheva, E.G. Lomaia, E.V. Morozova, A.K. Golenkov, T.I. Pospelova, O.A. Shukhov, M.S. Fominykh, G.A. Gusarova, L.A. Kuz’mina, A.O. Abdullaev, I.S. Martynkevich

  294-316

  01.07.2017

• Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life

  Tat’yana Ivanovna Ionova, N.B. Bulieva, O.Yu. Vinogradova, T.A. Gritsenko, L.K. Kozlova, G.B. Kuchma, E.G. Lomaia, E.R. Machyulaitene, T.P. Nikitina, N.V. Novitskaya, A.Yu. Rodionova, E.I. Usacheva, T.V. Shneider

  206-217

  01.04.2017

• Clinical and Hematological Characteristics of Patients with Chronic Myeloid Leukemia under Present-Day Conditions: Results of the Russian Part of International Multi-Center Prospective EUTOS Population-Based CML Study

  Ol’ga Veniaminovna Lazareva, A.G. Turkina, E.Yu. Chelysheva, I.A. Tishchenko, M.A. Galaiko, O.M. Senderova, V.M. Pepelyaeva, S.V. Meresii, A.S. Luchinin, G.I. Milyutina, L.V. Gavrilova, L.B. Avdeeva, O.Yu. Vinogradova, S.M. Kulikov

  65-74

  01.01.2017

• Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors

  Galina Anatol’evna Gusarova, A.G. Turkina

  474-484

  01.10.2016

• WT1 Gene Overexpression in Oncohematological Disorders: Theoretical and Clinical Aspects (Literature Review)

  Nikolai Nikolaevich Mamaev, Ya.V. Gudozhnikova, A.V. Gorbunova

  257-264

  01.07.2016

• PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells

  E.S. Kolotova, V.V. Tatarskii, A.A. Zeifman, O.V. Stroganov, V.S. Stroilov, I.Yu. Titov, F.N. Novikov, A.A. Kalinina, G.G. Chilov, Aleksandr Al’bertovich Shtil’

  1-5

  01.01.2016

• Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy

  K.M. Abdulkadyrov, Vasilii Anatol’evich Shuvaev, I.S. Martynkevich, M.S. Fominykh, N.A. Potikhonova, I.I. Zotova, V.Yu. Udal’eva, R.A. Golovchenko, N.V. Shakhvorostova, D.I. Shikhbabaeva, M.N. Zenina, S.A. Tiranova, S.A. Kudryashova, L.S. Martynenko, M.P. Ivanova, N.Yu. Tsybakova, E.V. Petrova, L.B. Polushkina, E.V. Kleina

  54-60

  01.01.2016

• Second Generation Tyrosine Kinase Inhibitors and Their Toxicity in Treatment of Patients in Chronic Phase of Chronic Myeloid Leukemia

  N.S. Lazorko, Elza Galaktionovna Lomaia, E.G. Romanova, E.I. Sbityakova, E.R. Machyulaitene, P.A. Butylin, A.Yu. Zaritskii

  302-308

  01.07.2015

• Diagnostic Strategy for Detection of Typical and Atypical BCR-ABL Fusion Gene Transcripts in Chronic Myeloid Leukemia

  O.V. Nikulina, Grigorii Anatol’evich Tsaur, T.O. Riger, Yu.A. Yakovleva, A.S. Demina, E.R. Semenikhina, T.V. Spil’nik, LI Savel’ev, L.G. Fechina

  161-168

  01.04.2015

• Haploidentical hematopoietic stem cell transplantation in children with acute myeloid leukemia: evolution of method and our data

  N.N. Subbotina, I.S. Dolgopolov, A.V. Popa, V.K. Boyarshinov, R.I. Pimenov, G.L. Mentkevich

  131-136

  01.04.2014

• Role of tyrosine-kinase inhibitor selectivity in development of adverse effects during treatment of chronic myeloid leukemia

  A.A. Zeifman, E.Yu. Chelysheva, A.G. Tukrina, G.G. Chilov

  16-27

  01.01.2014

• Current best options for first line treatment of chronic phase chronic myeloid leukemia

  R. Hehlmann, S. Saußele

  9-15

  01.01.2014

• Genfatinib® therapy for chronic-phase chronic myeloid leukemia in routine clinical practice

  T.V. Chagorova, V.V. Yablokova, P.A. Borkina, N.A. Pryanikova

  434-438

  01.10.2013